TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01307917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavonoids
Description: for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavonoids
Description: for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: flavonoids
Description: for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: flavonoids
Description: for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
Study: NCT03801824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index
Description: Subjects will be advised to eat low glycemic index foods
Study: NCT00088959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02180802

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motivational interviewing with parental involvement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Study: NCT03193658

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracolumbar Interfascial Plane (TLIP) block
Description: A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.~The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: I.V drug based multimodal approach
Description: A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
Study: NCT00203944

Intervention type: BEHAVIORAL
Intervention: Behavioral, Development
Study: NCT03032601

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: N-acetyl Cysteine
Description: The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
Study: NCT00673725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Locobase® REPAIR
Description: emollient
Study: NCT02344797

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures \>185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
Study: NCT03345888

Intervention type: OTHER
Intervention: predictive power of end-tidal carbon dioxide
Description: end-tidal carbon dioxide predicts resuscitation outcomes

Intervention type: OTHER
Intervention: predictive power of end-tidal carbon dioxide
Description: end-tidal carbon dioxide predicts resuscitation outcomes
Study: NCT02811588

Intervention type: DEVICE
Intervention: Non-invasive ventilation
Study: NCT03837119

Intervention type: OTHER
Intervention: pregnancy outcome
Description: descriptive statistics of variables

Intervention type: OTHER
Intervention: pregnancy outcome
Description: descriptive statistics of variables
Study: NCT01659346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Variceal Ligation
Description: Endoscopic Variceal Ligation every 3 weeks till eradication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
Study: NCT02060266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will receive a single dose subcutaneously (s.c., under the skin).
Study: NCT00606840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: large changes in eating and activity
Description: Behavioral self-regulation interventions to prevent weight gain in young adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: small changes in eating and activity
Description: Behavioral self-regulation interventions to prevent weight gain in young adults.
Study: NCT02759887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fludeoxyglucose F18 (FDG)
Description: Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fludeoxyglucose F18 (FDG)
Description: Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
Study: NCT05210153

Intervention type: DRUG
Intervention: Sertraline
Description: Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia.

Intervention type: DRUG
Intervention: Sertraline
Description: Drug: Sertraline, a selective serotonin reuptake inhibitor (SSRI), is commercially known as Sidata® or Zoloft® in Serbia. The recommended dose for Major depressive disorder is 100 mg/day. It is recommended to start therapy with 50 mg/day, and in the case of lack of therapeutic effect dose should be increased in 50 mg increments every 2 weeks until intended pharmacological effect is reached. Dose can be increased up to the maximum dose is 200 mg/day. Sertraline is also indicated for treatment of Obsessive-compulsive disorder, Generalized anxiety disorder, Social anxiety disorder (Social phobia), Panic disorder (with or without agoraphobia) and Post-traumatic Stress Disorder by Medicines and Medical Devices Agency of Serbia.~Drug levels are expected to be 50% higher in CYP2C19 poor metabolizers as compared to normal metabolizers, but no specific dosing recommendations are given by the Medicines and Medical Devices Agency of Serbia.
Study: NCT02900495

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electric nerve stimulation
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electric nerve stimulation
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcutaneous electric nerve stimulation
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electric nerve stimulation
Description: electrodes placed per treatment arm, performed at bedtime, session time 15 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
Study: NCT01966419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ornithine phenylacetate
Description: Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo intravenous infusion
Description: Placebo for continuous IV infusion that is visually identical to the experimental product
Study: NCT00956631

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Interlaminar Decompression
Description: The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
Study: NCT02330757

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol valerate
Description: Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is \< 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential Clomiphene citrate and Gonadotropin
Description: Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle \> 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
Study: NCT01671150

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endotoxin
Description: Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: endotoxin
Description: Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
Study: NCT00393263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimecrolimus and clobetasol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clobetasol 0.05% cream
Description: twice daily for three months
Study: NCT01732471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
Study: NCT03493750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral and dental evaluation
Description: Mouth inspection done by a nurse, in order to count missing, coloured, injured teeth, and evaluate dental plaque, halitosis, inflammatory gums, mucosal injuries, low masticatory surface.
Study: NCT03824821

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00001656

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: tablet; 5-20mg/day; 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: tablet; 12.5-900mg/day; 8 weeks
Study: NCT00725101

Intervention type: DRUG
Intervention: Treatment for Fibromyalgia
Description: FM participants starting any new pharmacologic FM agent.
Study: NCT03644056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC-001
Description: Different IMC-001 dose level for each cohort group (IMC-001 2 mg/kg etc. every 2 weeks)
Study: NCT00976209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg
Description: Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg
Description: Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
Study: NCT03796819

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lymphadenectomy
Description: Patients would undergo routine hepatoduodenal lymphadenectomy at the time of ICC resection
Study: NCT01939626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single-step medium
Description: This medium will allow in vitro culture of human embryos for 5/6 days

Intervention type: DEVICE
Group type: OTHER
Intervention: Standard culture medium
Description: This culture system needs media change on day 3 of culture.
Study: NCT03984227

Intervention type: GENETIC
Intervention: Taking peripheral blood samples
Description: quantitative real-time polymerase chain reaction

Intervention type: GENETIC
Intervention: Taking peripheral blood samples
Description: quantitative real-time polymerase chain reaction
Study: NCT01920867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RB (Retrobulbar)
Description: Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RB (Retrobulbar)
Description: Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RB (Retrobulbar)
Description: Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ST (Subtenon)
Description: Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ST (Subtenon)
Description: Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ST (Subtenon)
Description: Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV (Intravenous)
Description: Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV (Intravenous)
Description: Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IV (Intravenous)
Description: Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVIT (Intravitreal)
Description: Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IO (Intraocular)
Description: Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
Study: NCT03796338

Intervention type: DEVICE
Intervention: Sleep Profiler
Description: Patients are observed through a Sleep profiler, routinely used in the intensive care unit (ICU). This device is applied at every patient in the ICU and it acquires EEG, electrooculography, and electromyography from three frontopolar EEG signals.
Study: NCT03962231

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Unloading Exercise Program
Description: Patients in this group will perform semi-closed kinetic chain elevation exercises, deltoid reeducation exercises, assisted arm elevation and scapular control exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rotator Cuff Loading Exercise Program
Description: Patients in this group will perform conventional exercises focusing on lateral rotation, medial rotation and arm elevation.
Study: NCT04392167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a/LCI-OCT imaging probe
Description: a/LCI and OCT imaging measurements of several locations in the esophagus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: esophageal biopsy
Description: biopsies of esophageal tissue imaged by a/LCI-OCT probe
Study: NCT01882881

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy American Control Diet
Description: The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (\~250 mg) than the typical consumption practices (15g and 278 mg, respectively).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark Chocolate/Cocoa Diet
Description: The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide \~33% of calories from fat. The SFA (\~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (\~9g).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond Diet
Description: The Almond Diet will include 1.5 oz of almonds daily and provide \~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing \~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dark Chocolate/Cocoa + Almond Diet
Description: This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at \~34-35% and the SFA will match that of the Almond Diet at \~8-9%. The fiber content of this diet will be highest (\~35g); cholesterol will remain ≤200 mg/day.
Study: NCT04234269

Intervention type: OTHER
Intervention: Assessment
Description: Evaluation forms will be applied to the patients who meet the inclusion criteria by face to face interview method.The sociodemographic information of the patients and the time taken to answer the questions in the questionnaires will vary according to each patient, but will take approximately 45 minutes. The second interview will be conducted with the patients for test-retest application at 1 week intervals.
Study: NCT01267201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: powder for oral suspension 4 mg/mL single dose (8 mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: powder for oral suspension 4 mg/mL singe dose (8 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: tablet 32 mg single dose
Study: NCT00291161

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in Dementia Care
Description: Partners in Dementia Care is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:~Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient.